The Bredesen Protocol is a multi-component lifestyle program designed to prevent and reverse cognitive decline, particularly in early-stage Alzheimer’s disease and mild cognitive impairment. Developed by neuroscientist Dale Bredesen, it treats Alzheimer’s not as a single disease but as a collection of related conditions driven by different underlying causes, each requiring a tailored combination of diet, exercise, sleep optimization, stress reduction, and targeted supplementation. The program is also known as the ReCODE (Reversal of Cognitive Decline) Protocol.
The Six Subtypes of Alzheimer’s
Central to the Bredesen Protocol is the idea that Alzheimer’s disease isn’t one condition with one cause. Instead, the protocol classifies cognitive decline into six subtypes, each linked to different metabolic problems. The treatment plan you follow depends on which subtype (or combination) applies to you.
Inflammatory (“Hot”): One of the most common subtypes, driven by chronic inflammation from sources like infections, gum disease, gut permeability, autoimmune conditions, or long-term stress. In this model, the brain produces amyloid proteins as a protective response to inflammation, but those proteins eventually interfere with communication between neurons.
Atrophic (“Cold”): Caused by declining levels of hormones and nutrients the brain depends on for repair, including estrogen, testosterone, thyroid hormones, and vitamin D. Without adequate levels, neurons shrink and lose their connections.
Glycotoxic (“Sweet”): A hybrid of inflammation and insulin resistance, sometimes called Type 1.5. Chronically elevated blood sugar damages small blood vessels and impairs the energy-producing structures inside brain cells, leading to oxidative stress.
Toxic (“Vile”): Linked to exposure to heavy metals, mold-produced toxins (mycotoxins), or chemical pollutants that accumulate silently over years before symptoms appear.
Vascular (“Pale”): Occurs when restricted blood flow starves the brain of oxygen and glucose. This subtype is common in people with high blood pressure, elevated cholesterol, or clotting disorders.
Traumatic (“Head Injury-Related”): Triggered by past head injuries, even those that happened decades earlier, which can set off lasting inflammation and metabolic dysfunction. This type frequently overlaps with others.
The KetoFLEX 12/3 Diet
The dietary backbone of the protocol is called KetoFLEX 12/3, a plant-heavy, mildly ketogenic eating pattern built around time-restricted eating. The name breaks down into three parts. “Keto” refers to a diet that shifts the body toward burning fat for fuel. “FLEX” stands for metabolic flexibility, the ability to switch between using glucose and fat as energy sources. “12/3” describes the fasting schedule: you fast for at least 12 hours every day, and your last meal ends at least 3 hours before bed.
In practice, this means if you go to sleep at 10 p.m., you stop eating by 7 p.m. and don’t eat again until at least 7 a.m. The diet emphasizes non-starchy vegetables, healthy fats, and modest amounts of protein, while limiting sugar, processed foods, grains, and dairy. The goal is to reduce insulin resistance and provide the brain with ketones as an alternative fuel source, since impaired glucose metabolism in the brain is a well-documented feature of Alzheimer’s.
Other Core Components
Diet is only one piece. The full protocol addresses dozens of variables that Bredesen argues collectively contribute to cognitive decline. Exercise is a major pillar, with the program recommending both aerobic activity and strength training to improve blood flow to the brain and support the growth of new neural connections. Sleep optimization is another focus, since the brain clears waste products (including amyloid) primarily during deep sleep. The protocol typically recommends seven to eight hours per night and may suggest sleep studies for people with suspected sleep apnea.
Stress management techniques like meditation are included to lower cortisol, a stress hormone that can damage the brain’s memory center when chronically elevated. Cognitive stimulation through brain training exercises is also part of the program. Depending on your subtype, the protocol may call for specific supplements targeting hormone levels, gut health, or nutrient deficiencies, along with blood tests and other lab work to track dozens of biomarkers over time.
The Toxin Subtype and Its Challenges
The toxic subtype is one of the more controversial elements of the protocol. Bredesen has proposed that mycotoxin exposure (from indoor mold) could represent a distinct form of dementia, though the Alzheimer’s Drug Discovery Foundation notes this more likely describes a mycotoxin-triggered cognitive impairment rather than pathologically defined Alzheimer’s disease. There is no direct evidence that mycotoxin exposure causes Alzheimer’s or that mold-exposed individuals have a higher probability of developing it.
Diagnosing toxic exposure is also difficult. While some mycotoxin levels can be measured in blood or urine, validated tests are lacking for most of them. Detecting antibodies to mold may indicate exposure to mold itself but not necessarily to the harmful toxins it produces. Treatment options are limited as well. There are currently no effective methods proven to clear mycotoxins from the body. Some practitioners use sequestering agents like activated charcoal or clay to try to prevent further absorption, but the most reliable approach is simply avoiding the source of exposure.
What the Clinical Evidence Shows
The most frequently cited evidence for the Bredesen Protocol comes from case series and a proof-of-concept trial. In one published report, 84% of patients with mild cognitive impairment or early dementia showed improvement on the protocol. That number sounds striking, but context matters. The study was small, lacked a control group, and did not include long-term follow-up. Case series, by design, track people who stuck with a complex program and agreed to be documented, which creates selection bias. People who dropped out or didn’t improve are less likely to appear in the results.
No large-scale, randomized controlled trial has yet confirmed that the protocol can reverse Alzheimer’s disease. This is the standard of evidence the broader medical community looks for before endorsing a treatment, and it’s the gap that draws the most criticism.
What Critics and Experts Say
The Alzheimer’s research community has raised several concerns. Organizations like Alzheimer’s San Diego have stated plainly that any entity claiming to “reverse” or “cure” Alzheimer’s disease should be viewed with skepticism and caution. While there is compelling evidence that diet, exercise, and lifestyle choices play a significant role in cognitive health, no known diet, supplement, or exercise regimen has been shown to cure or reverse the course of Alzheimer’s disease.
Critics also point to potential conflicts of interest. The protocol often involves purchasing specific supplements, sometimes at a premium, from affiliated sources. Alzheimer’s advocacy groups warn consumers to be wary of treatments promoted by organizations or individuals with a financial stake in the recommendations. The full program, including practitioner visits, extensive lab testing, and supplements, can cost thousands of dollars out of pocket and is generally not covered by insurance.
That said, many of the individual components of the protocol are supported by independent research. Regular exercise, quality sleep, a Mediterranean-style diet, stress management, and controlling cardiovascular risk factors all have evidence behind them as strategies to support brain health. The debate isn’t really about whether these habits matter. It’s about whether packaging them together as a protocol can reverse a neurodegenerative disease, and whether the specific subtyping system and supplement recommendations are backed by sufficient evidence to justify the cost and the claims.